Lenvatinib delays Thyroid Cancer Progression better than Placebo

February 12, 2015 8:45 PM

2 0

Lenvatinib delays Thyroid Cancer Progression better than Placebo

Findings of a new study have showed that Oral Lenvatinib is capable of delaying progression of advanced thyroid cancer by 18 months, compared with four months for patients treated with a placebo.

Findings of the study based on the results of a clinical trial are published in the February 12 issue of the New England Journal of Medicine. As many as 392 patients from 21 countries were enrolled in the study and all of them had thyroid cancer that displayed resistance to radioactive iodine.

Read more

To category page

Loading...